Oncotelic Therapeutics Featured in BioMedWire Editorial Highlighting CNS and Oncology Momentum

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the InvestorBrandNetwork. The article, titled "Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development," highlights growing pharmaceutical interest in clinical-stage assets supported by human data and features Oncotelic as an example of a diversified clinical-stage company. The editorial notes the company's recently expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology and CNS drug-delivery technologies designed to cross the blood–brain barrier.

The editorial's focus on drug-delivery breakthroughs and cross-indication research reflects broader industry trends where companies with validated platforms gain increased attention. Oncotelic's positioning within this context suggests recognition of its strategic approach to addressing high-unmet-need cancers and rare pediatric indications. The company's clinical-stage status, combined with its expanded intellectual property portfolio, creates a foundation for potential partnerships and development opportunities in competitive therapeutic areas.

BioMedWire serves as a specialized communications platform focusing on biotechnology, biomedical sciences and life sciences sectors. As part of the Dynamic Brand Portfolio at IBN, it provides access to wire solutions, article syndication to over 5,000 outlets, enhanced press release distribution, and social media distribution to millions of followers. The platform's broad reach and industry focus make editorial placements particularly valuable for companies seeking visibility among investors, journalists and the general public. Additional information about BioMedWire is available at https://www.BioMedWire.com.

The intellectual property expansion for OT-101 represents a significant development for Oncotelic, as TGF-β targeting has shown promise across multiple therapeutic areas. The platform's application in neurology, oncology and CNS drug-delivery technologies indicates a versatile approach to drug development. Technologies designed to cross the blood-brain barrier are particularly important for treating central nervous system disorders, where drug delivery remains a major challenge in pharmaceutical development.

Oncotelic's diversified approach extends beyond its directly owned pipeline through joint ventures and licensing arrangements. The company owns 45% of GMP Bio, a joint venture that advances complementary drug candidates in oncology and rare disease therapeutics. This strategic positioning allows the company to leverage external innovation while maintaining focus on its core development programs. The combination of internal development and strategic partnerships creates multiple pathways for value creation in competitive therapeutic markets.

The editorial placement comes at a time when pharmaceutical companies are increasingly seeking clinical-stage assets with human data validation. This trend reflects industry movement toward de-risked development opportunities, particularly in complex therapeutic areas like oncology and central nervous system disorders. Companies with protected intellectual property and demonstrated platform technologies stand to benefit from this shift in industry focus toward more advanced development candidates.